Rayaldee pill Opko Health announced that the Food and Drug Administration (FDA) has approved Rayaldee (calcifediol) extended-release capsules for the treatment of secondary hyperparathyroidism (SHPT) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The U.S. Food and Drug Administration has ...

THOUSAND OAKS, Calif., Feb. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary ...

The mechanism by which hyperuricemia increases SHPT risk is not completely understood. Hyperuricemia may be a contributing factor to secondary hyperparathyroidism (SHPT) in patients with chronic ...

Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended approval of etelcalcetide (Parsabiv, Amgen Europe BV) for the treatment of secondary ...

Results from a randomized, placebo-controlled study indicate that ergocalciferol is safe and effective in delaying the onset of secondary hyperparathyroidism in children with stage 2–3 chronic kidney ...

For patients with chronic kidney disease, the risk of elevated levels of parathyroid hormone, or hyperparathyroidism -- a significant complication that increases the risk of cardiovascular problems ...

Background A 17-year-old Filipino male hemodialysis patient presented for renal transplant evaluation. He had significant skeletal abnormalities characterized by bone pain, an inability to walk, and ...

However, despite suggestions that such secondarily stimulated hyperparathyroidism may become autonomous 12–14 convincing data regarding such a possibility are not available, owing to the great excess ...